Characteristicsa | Total | Norwegians | South Asians | Other | pb |
---|---|---|---|---|---|
Primary cardiovascular prevention in 1273 patients without known CVD | |||||
Proportions of patients on glucose lowering therapy, n/N (%) | |||||
HbA1c < 6.0% | 82/899 (9.1) | 62/563 (11.0) | 7/202 (3.5) | 13/134 (9.7) | 0.006 |
Proportions of patients on anti-hypertensive therapy, n/N (%) | |||||
SBP < 130 mmHg | 154/672 (22.9) | 98/514 (19.1) | 36/90 (40.0) | 20/68 (29.4) | <0.001 |
DBP < 65 mmHg | 25/671 (3.7) | 18/514 (3.5) | 6/89 (6.7) | 1/68 (1.5) | 0.193 |
Secondary cardiovascular prevention in 380 patients with known CVD | |||||
Proportions of patients on glucose lowering therapy, n/N (%) | |||||
HbA1c < 6.0% | 25/280 (8.9) | 24/209 (11.5) | 1/52 (1.9) | 0/19 (0.0) | 0.035 |
Proportions of patients on anti-hypertensive therapy, n/N (%) | |||||
SBP < 130 mmHg | 76/319 (23.8) | 55/262 (21.0) | 17/40 (42.5) | 4/17 (23.5) | 0.012 |
DBP < 65 mmHg | 26/319 (8.2) | 16/262 (6.1) | 6/40 (15.0) | 4/17 (23.5) | 0.009 |